SOFTBANK Group Corp chief executive Masayoshi Son held his first "pre-IPO summit" for the Japanese conglomerate's portfolio companies on Tuesday, introducing them to Wall Street investors who could be backing their stock market debuts.
The event, which was closed to the media and described by a source in attendance, illustrates how SoftBank is keen to prepare the ground for the initial public offerings of many of its holdings, after some of its portfolio companies performed poorly last year following their listings.
The gathering hosted institutional investors and was chaired by Mr Son and BlackRock Inc CEO Larry Fink. It included nine SoftBank-backed companies, including data storage company Cohesity, British financial technology firm OakNorth and financing group Greensill Capital, the source said. SoftBank declined to comment.
Mr Son, under pressure from hedge fund Elliott Management to rein in his mercurial investment style, is spending the week meeting Wall Street contacts in New York. He is having to defend his track record after several of its expensive bets on startups, including office space-sharing firm WeWork, soured.
SoftBank was aiming to raise US$108 billion in funds for a second Vision Fund. However, Mr Son said last month its launch had been delayed due to investor concerns about the performance of SoftBank's first US$100 billion Vision Fund.
As a result, Mr Son has said SoftBank may spend up to two years investing its own money in a bridge fund, to build a portfolio that will give investors enough confidence to participate in a second Vision Fund.
Two of the first Vision Fund's most high-profile investments, ride-hailing firm Uber Technologies Inc and workplace message app Slack Technologies Inc, are trading well below the prices at which they went public last year.
WeWork saw its potential valuation tumble by tens of billions of dollars before cancelling its IPO plans last year and being bailed out by SoftBank in a close to US$10 billion rescue financing deal. There have also been some IPO successes from the Vision fund, such and life science technology company 10x Genomics Inc and Vir Biotechnology Inc, which specialises in clinical-stage immunology. REUTERS